Chinese laboratory-animal model provider, breeding genetically engineered mice for biomedical research and drug development.
Chinese laboratory-animal model provider, breeding genetically engineered mice for biomedical research and drug development.
Sells live mice from a stock catalogue of its genetically engineered strains, a repeat revenue source because labs reorder animals for experiments, with custom model creation and testing services as add-ons. Sales go mainly to pharma, biotech and research institutes in China, so R&D budgets decide demand.
In one line: A Chinese Jackson Laboratory / Charles River mouse-model business.
Moat: narrow (scale, installed base, process know-how). Large, standardized mouse-model catalog and breeding scale that is slow for customers to replicate in-house.
Headquarters: Nanjing, China · Employees: 1,590
Size GemPharmatech (688046.SS) is a China Health Care company (Biotechnology) with a market value of $1.78B, the 1299th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥29.91 on 18 Nov 2026.
Performance Over six months the shares gained 39.0%, against -2.8% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue grew 25.0% over the last twelve months (peer median +10.8%); the operating margin is 22.3% (peer median -46.1%).
Valuation It trades at 51.9× forward earnings against a peer median of 22.6× (3rd most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +25%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.5 points above its cost of capital (12.6% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥941M | CN¥792M | CN¥687M | CN¥622M | CN¥516M |
| Revenue growth | — | +15% | +10% | +20% | — |
| Gross profit | CN¥684M | CN¥502M | CN¥421M | CN¥418M | CN¥367M |
| EBITDA | n/a | CN¥243M | CN¥188M | CN¥173M | CN¥147M |
| Net income | CN¥203M | CN¥143M | CN¥110M | CN¥159M | CN¥165M |
| Free cash flow | CN¥280M | CN¥139M | -CN¥2,830 | -CN¥78.4M | -CN¥74.1M |
| Capital expenditure | CN¥71.1M | CN¥105M | CN¥114M | CN¥206M | CN¥190M |
| Total debt | CN¥209M | CN¥291M | CN¥132M | CN¥122M | CN¥17.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| GemPharmatech 688046.SS | $1.78B | +39% | +25% | 22% | 51.9× | 33.0% |
| Charles River Laboratories CRL | $16.0B | +114% | -1% | 15% | 26.2× | 25.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688046.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.1% | -1.6% | 10th highest of 20 |
| 6-month return | +39.0% | -2.8% | 6th highest of 20 |
| Distance from 52-week high | -31.2% | -34.3% | 9th highest of 21 |
| Revenue growth (TTM) | +25.0% | +10.8% | 7th highest of 16 |
| Operating margin | 22.3% | -46.1% | 4th highest of 17 |
| Forward P/E | 51.9× | 22.6× | 3rd most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 33.0% | -7.6% | 2nd most demanding of 6 |
| Growth delivered (Del g) | +24.8% | +16.8% | 3rd highest of 6 |
| Hurdle (Req g minus delivered) | +8.1 pp | -27.1 pp | 3rd most demanding of 6 |
| ROIC minus cost of capital | +2.5 pp | -6.3 pp | 4th highest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 51.9× | 33.0% | +24.8% |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | n/a | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | n/a | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | n/a | n/a | n/a |
| Hemab Therapeutics COAG | United States | $1.83B | +48% | n/a | n/a | n/a | n/a | n/a |
| Vera Therapeutics VERA | United States | $1.85B | -26% | n/a | -4,160% | n/a | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $1.86B | -20% | -9% | 6% | 105.5× | 22.7% | +3.4% |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 18.1× | -12.1% | +15.0% |
| First Tracks Biotherapeutics TRAX | United States | $1.87B | +175% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | n/a | n/a | n/a |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 11.1× | -11.0% | +117.9% |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | n/a | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 27.6× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 7.5× | -7.6% | +33.5% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 22.6× | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 73.2× | 33.2% | +16.8% |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.62B | +28% | +8% | -1,463% | n/a | n/a | n/a |